Home|Journals|Articles by Year|Audio Abstracts

Original Article

J App Pharm Sci. 2024; 14(2): 174-183

Impact of duration of infusion on estimated blood amikacin levels: A study at the Central General Hospital in Yogyakarta, Indonesia

Esti Dyah Utami, Ika Puspitasari, Rizka Humardewayanti Asdie, Endang Lukitaningsih, Andaru Dahesihdewi.


The duration of infusion may influence the plasma drug level, thereby influencing effectiveness and toxicity. Intravenous amikacin (AMK) should not be given as a bolus. Instead, it is recommended to be administered via intermittent infusion over 30–60 minutes. This study aimed to determine differences in the estimated pharmacokinetic (PK)/pharmacodynamic parameters of AMK when administered via 30- versus 60-minute infusions, as well as the relationship with outcomes and toxicity. The data for this study were gathered from the medical records of adult inpatients treated with AMK at Dr Sardjito Hospital in Yogyakarta. Due to the lack of therapeutic drug monitoring, blood AMK levels were estimated using a pharmacokinetic formula. The results demonstrated that the duration of AMK infusion had an impact on the estimated AMK levels (Cmax, Cmin, and maximum concentration/minimum inhibitory concentration ratio). Estimated AMK Cmax and Cmin showed a significant correlation with mortality and signs of toxicity, and Cmin of

Key words: Amikacin; Duration of Infusion; Estimated blood level; Outcome; Toxicity

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Refer & Earn
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.